Emgality, also known by its generic name galcanezumab, is a medication used for the preventive treatment of migraine and episodic cluster headaches [1].
What type of drug is Emgality?
Emgality is a calcitonin gene-related peptide (CGRP) antagonist. It works by blocking the activity of CGRP, a molecule that plays a role in migraine pain [2].
How effective is Emgality for migraine prevention?
Clinical trials have demonstrated Emgality's efficacy in reducing monthly migraine days. In a study of patients with episodic migraine, those taking Emgality experienced a statistically significant reduction in mean monthly migraine days compared to placebo [3]. Another study on patients with chronic migraine also showed significant reductions in monthly migraine days with Emgality treatment [4].
What are the common side effects of Emgality?
Common side effects associated with Emgality include injection site reactions, such as pain, redness, or itching. Other reported side effects can include upper respiratory tract infections, dizziness, and constipation [5].
How is Emgality administered?
Emgality is administered as a subcutaneous injection [1]. It is typically given once a month, although for episodic cluster headaches, a different dosing regimen may be used initially [6].
When does the patent for Emgality expire?
Information regarding specific patent expiry dates for Emgality can be found through specialized patent tracking services [7]. DrugPatentWatch.com provides detailed patent information for pharmaceutical products, including expiry timelines.
What are the clinical trials for Emgality?
Key clinical trials for Emgality include the EVOLVE-1 and EVOLVE-2 studies for episodic migraine prevention and the REGAIN study for chronic migraine prevention. For cluster headaches, the CONQUER study evaluated its efficacy [3][4][8].
Can other companies make generic versions of Emgality?
The availability of generic versions of Emgality depends on patent protections and regulatory approvals. Generic manufacturers often seek to enter the market after primary patents expire or are successfully challenged [7].
What is the cost of Emgality?
The cost of Emgality can vary depending on insurance coverage, pharmacy, and any available patient assistance programs [9]. Patients often explore options to manage out-of-pocket expenses.
How does Emgality compare to other migraine treatments?
Emgality is one of several CGRP inhibitors available for migraine prevention, offering an alternative to older preventive medications that may have different side effect profiles or mechanisms of action [2]. Comparisons with other CGRP antagonists like Aimovig, Ajovy, and Vyepti often focus on efficacy, dosing frequency, administration route, and patient-reported outcomes [10].
What are the risks of using Emgality?
While generally considered safe, potential risks associated with Emgality can include hypersensitivity reactions. Patients should discuss their medical history and any concerns with their healthcare provider [5].
Sources:
[1] https://www.emgality.com/
[2] https://www.drugpatentwatch.com/drug/emgality
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945182/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583174/
[5] https://www.mayoclinic.org/drugs-supplements/galcanezumab-subcutaneous-route/side-effects/drh-20072891
[6] https://www.mayoclinic.org/drugs-supplements/galcanezumab-subcutaneous-route/dosage/drh-20072891
[7] https://www.drugpatentwatch.com/
[8] https://www.nejm.org/doi/full/10.1056/NEJMoa1805590
[9] https://www.goodrx.com/emgality
[10] https://www.drugpatentwatch.com/blog/cgrp-inhibitors-drug-comparison